Trimethylacetaldehyd-(trimethylacetylhydrazon) | 77637-83-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Trimethylacetaldehyd-(trimethylacetylhydrazon)
• 英文别名: N-(2,2-dimethylpropylideneamino)-2,2-dimethylpropanamide
• CAS: 77637-83-3
• 化学式: C₁₀H₂₀N₂O
• 分子量: 184.282
• InChiKey: CGXDNXAYMLHFOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Dimeres Nitroso-neopentan 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 Trimethylacetaldehyd-(trimethylacetylhydrazon)
  参考文献：
  名称：

  Duschek,C. et al., Journal fur praktische Chemie (Leipzig 1954), 1971, vol. 313, p. 949 - 955

  摘要：

  DOI：

文献信息

• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。
• CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF
  申请人：GEIERSTANGER Bernhard Hubert

  公开号：US20160311853A1

  公开（公告）日：2016-10-27

  Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
• AURISTATIN DERIVATIVES AND CONJUGATES THEREOF
  申请人：Geierstanger Bernhard Hubert

  公开号：US20170121282A1

  公开（公告）日：2017-05-04

  Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
• AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE
  申请人：Grunewald Jan

  公开号：US20170355731A1

  公开（公告）日：2017-12-14

  The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:
• SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
  申请人：Seagen Inc.

  公开号：US20210138077A1

  公开（公告）日：2021-05-13

  The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.